NP与VIP方案治疗晚期非小细胞肺癌近期疗效观察  

Comparison of short-term efficacy between the NP and VIP regimens in the treatment of advanced non-small-cell lung cancer

作　　者：许玉香 王志东 陈立军 何琼华 

机构地区：[1]湖南省湘潭市一医院肿瘤内科,411101

出　　处：《中国肿瘤临床与康复》2005年第3期260-262,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的观察诺维本(NVB)与顺铂(DDP)组成的NP方案和足叶乙甙(Vp16)与异环磷酰胺(IFO)、顺铂(DDP)组成的VIP方案对晚期非小细胞肺癌(NSCLC)的近期疗效和毒副作用。方法将经病理组织学或细胞学证实的53例晚期NSCLC患者随机分为A组(NP方案组,22例)和B组(VIP方案组,31例),分别给予NVB+DDP及Vp16+IFO+DDP治疗,21d为一周期。结果A组有效率为50.0%,B组41.9%(P=1.43)。两组剂量限制性毒性反应均为骨髓抑制,胃肠道反应和静脉炎亦常见。A组Ⅲ、Ⅳ度白细胞下降发生率为18.2%,B组45.2%(P<0.05);A组静脉炎发生率为40.9%,B组3.2%(P<0.05),但均可耐受。结论NP方案和VIP方案治疗NSCLC疗效相近,毒性反应均可耐受。但NP方案骨髓抑制较VIP方案轻微,可作为NSCLC一线治疗方案中的首选。Objective To compare the short-term therapeutic efficacy,toxicity and side reactions between norelbine plus cisplatin(NP regimen)and etoposide plus ifosfamide and cisplatine(VIP regimen)in the treatment of non-small-cell lung cnacer(NSCLC).Methods Eifty-three patients with cytologically and pathologically confirmed NSCLC were divided into two groups(A and B).Twenty-two cases in the A group received NE regimen chemotherapy.Thirty-one cases in the B group received VIP regimen chemotherapy.Both regimens were repeated after a cycle of 21 days.Results Response rates were 50.0%(A group)and 41.9%(B group) respectively for NP and VIP regimens(P=1.43).The dose-limiting toxicity was myelosuppresion which was seen in both groups.Gastrointestinal reaction and local phlebitis were also observed.The rates of grade Ⅲ-Ⅳ leukopemia were 18.2%(A group) and 45.2%(B group) and local rates of phlebitis were 40.9%(A group)and 3.2%(B group),with statistical difference between the two groups(P<0.05).Conclusion The therapeutic effectiveness of NP regimen was similar to that of VIP regimen,but the myelosuppression of NP regimen was milder than that of VIP regimen,so norelbin plus cisplatine may be used as first line chemotherapy for NSCLC.

关 键 词：肺肿瘤 化学疗法 诺维本 顺铂 异环磷酰胺 足叶乙甙 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]